Physician profile
David Tian
NPI 1598080129
$1,968.49
in general payments reported to CMS, 2019-2025
13 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $305 · 2021: $320 · 2022: $313 · 2023: $352 · 2024: $50.59 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $603.34 | 2019-2023 | Xarelto |
| Pfizer INC. | $383.58 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $303.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.72 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $131.37 | 2019-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $82.64 | 2019-2025 | |
| Amgen INC. | $73.68 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $61.96 | 2019-2025 | General - Therapies |
| Edwards Lifesciences Corporation | $55.81 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $39.85 | 2022 | |
| Abbott Laboratories | $29.97 | 2024 | Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $20.57 | 2023 | Andexxa |
| Novo Nordisk INC | $18.19 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.